

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 405 788 A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 90306401.2

(51) Int. Cl.⁵: **C07C 323/47, C07C 323/60,
C07C 319/20, A61K 31/095**

(22) Date of filing: 12.06.90

(30) Priority: 29.06.89 JP 167497/89

(43) Date of publication of application:
02.01.91 Bulletin 91/01

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE


(71) Applicant: **SHIONOGI SEIYAKU KABUSHIKI
KAISHA** trading under the name of
SHIONOGI & CO. LTD.TD.
1-8, Doshomachi 3-chome Chuo-ku
Osaka 541(JP)

(72) Inventor: **Matsumoto, Saichi**
3-2-11 Fushiodai
Ikeda-shi, Osaka(JP)
Inventor: **Mizui, Takuji, C/o Associate Prof Pak
H. Chan**
Department of Neurology, School of
Medicine
Uni.of California San Francisco CA
94143(US)
Inventor: **Doteuchi, Masami**
33-3 Ogurahigashimachi
Hirakata-shi, Osaka(JP)

(74) Representative: **Hardisty, David Robert et al**
BOULT, WADE & TENNANT 27 Furnival
Street
London EC4A 1PQ(GB)

(54) **Di-tert-butyl(hydroxy)phenylthio substituted hydroxamic acid derivatives.**

(57) (Di-tert-butylhydroxyphenyl)thio substituted hydroxamic acid derivatives of the formula:



wherein X is straight or branched C₁ to C₁₆ alkylene which may be attached to Y through phenylene, provided that X is not n-butyl-methylene; Y is CO-N(OH) or N(OH)-CO; and R is hydrogen or straight or branched C₁ to C₉ alkyl, C₃ to C₉ cycloalkyl, aryl, or aralkyl, provided that R is not hydrogen when Y-R is N(OH)-CO-R; or a pharmaceutically acceptable salt thereof; useful in treating arteriosclerosis, ulcer, inflammation, allergy, or the like.

EP 0 405 788 A2

DI-TERT-BUTYL(HYDROXY)PHENYLTHIO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES


This invention relates to hydroxamic acid derivatives substituted by a di-tert-butyl(hydroxy) phenylthio residue which may be useful as medicines. More particularly, it relates to hydroxamic acid derivatives substituted by a di-tert-butyl(hydroxy)phenylthio residue, which inhibits LDL (Low Density Lipoprotein) from being incorporated into macrophages, whereby they may be useful as an anti-arteriosclerosis agent.

5 In addition, they also have anti-oxidation activity and show preventive activity in oxidation of lipid, ulcer formation, and lipoxygenase action, whereby they may be useful as vessel disorder agents, anti-asthma agents, anti-diabetes agents, anti-ulcer agents, anti-inflammatory agents, anti-tumour agents, anti-allergy agents, and the like.

Atherosclerosis is recognised as a significant symptom which occurs in an initial stage of arteriosclerosis, in such a manner that lipid material, mainly consisting of cholesterol, moves into the arterial wall accompanied by hyperplasia and consequent sclerosis. Atherosclerosis has been thought to be due not to a single factor but to accumulated factors over a long period of time, such as hypertension, hyperlipemia, excessive cigarette smoking, obesity, diabetes mellitus, hyperuricemia, stress, heredity, lack of exercise, etc. Among these factors, the behavior of cholesterol existing as LDL in blood is noted. What is especially
15 important is penetration of LDL into the arterial wall and the incorporation of LDL into macrophages, and the subsequent accumulation of cholesterol at the wall and vessel disorder. In addition, the following factors are considered to promote the occurrence of atherosclerosis: the increase of blood cholesterol due to troubles in the incorporation of LDL into the liver and the metabolism of LDL in liver, the hydrodynamic state of blood due to the change in the physical properties of red blood cells, damage to the endothelium, the
20 abnormal hyperplasia of the arterial wall and the depression of lipid utilization in arterial tissues, and the like.

For the drug therapy of atherosclerosis, there have theretofore been used anti-arteriosclerosis agents such as pyridinol carbamate; lipid lowering agents such as chlorfibrate, nicotinic acid, alpha-tyroxine and cholestyramine; and anti-platelet agents such as dipyridamole and aspirin, etc. The analogues which have
25 activity in lowering lipids in serum or lipoxygenase inhibitory activities are disclosed in US 4,029,8812, US 4,076,841, US 4,078,084, EP 273,451, or the like. The hydroxamic acid derivatives which have lipoxygenase inhibitory activity are disclosed in JP. Unexam. Publn. No. 86-257951, JP. Unexam. Publn. No. 86-251640, JP. Unexam. Publn. No. 86-251641, JP. Unexam. Publn. No. 86-251642, JP. Unexam. Publn. No. 88-225340, JP. Unexam. Publn. No. 89-104033, JP. Unexam. Publn. No. 89-153658, EP 279263, or the like.
30 This invention is characterized by the hydroxamic acid derivatives having a di-tert-butyl(hydroxy)phenylthio moiety and is new. GB 2,212,153 generally discloses a certain compound of the present invention.

(Di-tert-butylhydroxyphenyl)thio substituted hydroxamic acid derivatives of the formula:



wherein X is straight or branched C₁ to C₁₆ alkylene which may be attached to Y through phenylene, provided that X is not n-butylmethylene; Y is CO-N(OH) or N(OH)-CO; and R is hydrogen, straight or branched C₁ to C₉ alkyl, C₃ to C₉ cycloalkyl, aryl, or aralkyl, provided that R is not hydrogen when Y-R is N(OH)-CO-R; or a pharmaceutically acceptable salt thereof.

45 Said compounds which inhibit LDL from being incorporated by macrophages and oxidizing fatty acids are useful in treating arteriosclerosis, ulcer, inflammation, or allergy.

Description of the Preferred Embodiments


50

It is generally considered that normal LDL are not incorporated by reticuloendothelial cells (scavenger cells) such as macrophages and kupffer cells, but denaturated LDL are incorporated through a receptor for denaturated LDL. Also, it is considered that even when a large amount of cholesterol is accumulated in cells, the receptor for denaturated LDL does not decrease in number in cells, so that the accumulation of

cholesterol is unlimitedly enhanced whereby the conversion of reticuloendothelial cells into foam cells may take place resulting in establishment of arteriosclerosis. It is found that the lipoxygenase in endothelium plays an important role in oxidation and denaturation of LDL [D. Steinberg et al., Proc. Natl. Acad. Sci., 86, 1046, (1989)] and it suggests the applicability of the compounds having lipoxygenase inhibitory activity as anti-arteriosclerosis agents.


From the view, as discussed above, that inhibition of the production of denaturated LDL is useful in the prophylaxis or treatment of atherosclerosis, it is desired to develop drugs which can do that.

As a result of extensive studies the present inventors provided compounds of the following formula:




wherein X is straight or branched C₁ to C₁₅ alkylene which may be attached to Y through phenylene, provided that X is not n-butylmethylene; Y is CO-N(OH) or N(OH)-CO; and R is hydrogen, straight or branched C₁ to C₉ alkyl, C₃ to C₉ cycloalkyl, aryl, or aralkyl, provided that R is not hydrogen when Y-R is N(OH)-CO-R; or a pharmaceutically or veterinarily acceptable salt thereof, and found that they have excellent anti-oxidative activity such as LDL denaturation inhibitory activity, lipoxygenase inhibitory activity, or the like and completed this invention.

In more detail, this invention provides compounds of the formula (Ia):



wherein Xa is straight or branched C₁ to C₁₅ alkylene which may be attached to Y through phenylene, provided that Xa is not n-butylmethylene; Y is CO-N(OH) or N(OH)-CO; and R is hydrogen, straight or branched C₁ to C₉ alkyl, C₃ to C₉ cycloalkyl, aryl, or aralkyl, provided that R is not hydrogen when Y-R is N(OH)-CO-R;

or a pharmaceutically or veterinarily acceptable salt thereof.
and compounds of the formula (Ib):



wherein Xa is straight or branched C₁ to C₁₅ alkylene; Y is CO-N(OH) or N(OH)-CO; and R is hydrogen, straight or branched C₁ to C₉ alkyl, C₃ to C₉ cycloalkyl, aryl, or aralkyl, provided that R is not hydrogen when Y-R is N(OH)-CO-R; or a pharmaceutically or veterinarily acceptable salt thereof.

In this specification, the term "straight or branched C₁ to C₁₅ alkylene" in "X" or "Xa" includes, for example, straight alkylene, e.g., methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, nonamethylene, decamethylene, undecamethylene, dodecamethylene, tridecamethylene, tetradecamethylene, pentadecamethylene, branched alkylene e.g., methylmethylene, dimethylmethylene, propylene, ethylethylene, 1,1-dimethylethylene, n-butylmethylene, 1,1-dimethyltrimethylene, 1,1-dimethyltetramethylene, 1-ethyltetramethylene, 1,1-dimethylpentamethylene, 1-methylhexamethylene, 1,1-dimethylhexamethylene, 1,1-dimethylheptamethylene, 1-methyloctamethylene, 1,1-dimethyloctamethylene, 1,1-dimethylnonamethylene, 1-methyldecamethylene, 1,1-dimethyldecamethylene, 1-methylundecamethylene, 1,1-dimethylundecamethylene, 1,1-dimethyldodecamethylene, 1-methyltridecamethylene, 1,1-dimethyltridecamethylene, 1-methyltetradecamethylene, 1,1-dimethyl-

tetradecamethylene, or 1,1- dimethylpentadecamethylene, and the like. "X" or "Xa" is not simply n-butylmethylene.

Phenylene may intervene between X and Y as shown in the formula (Ib).

The term "straight or branched C₁ to C₉ alkyl" in "R" includes, for example, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl, isohexyl, n-heptyl, n-octyl, n-nonyl, or the like. The term "C₃ to C₉ cycloalkyl" includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and the like. The term "aryl" means an aromatic moiety which may have one or more substituents, including, for example, phenyl, cumenyl (o-, m-, p-), mesityl, tolyl (o-, m-, p-), xylyl (2,3-; 2,4-; 2,5-; 3,4-; 3,5-), naphthyl (1-, 2-), indenyl (2-, 3-), or the like. The term "aralkyl" means C₁ to C₄ alkyl (e.g., methyl, ethyl, propyl, or butyl) which is substituted by one or more aforementioned "aryl" at any of the positions, including, for example, benzyl, diphenylmethyl, triphenylmethyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, naphthylmethyl, indenylmethyl, and the like.

The terms "leaving group" in "Z" means "nucleophilic leaving group" which is ordinarily used including hydroxy, alkoxy, anhydride residue, halogen (e.g., bromine, chlorine, iodine), amine, or the like.

As a preferable "R", it is exemplified that straight or branched C₁ to C₈ alkyl, for example, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, or n-octyl; C₃ to C₈ cycloalkyl, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; aryl, for example, phenyl, or p-tolyl; aralkyl, for example, benzyl, 4-methylbenzyl, or phenethyl.

The compounds of formula (I) may form a salt with alkali metal (e.g., lithium, sodium, potassium, or the like), with alkaline earth metal (e.g., calcium or the like), with amino acids (e.g., lysine, arginine, or the like), with organic bases (e.g., triethylamine, dicyclohexylamine, or the like), or the like.


The compounds of this invention can be prepared according to a conventional method for hydroxamic acid derivatives, for example, as shown in "Organic Functional Group Preparations", Vol. III, Alfred T. Blomquist *et al.*, Academic Press, New York, 1972.

The compounds (I) of this invention can be prepared by the usual methods for preparations of hydroxamic acid such as (1) reaction of a carboxylic acid derivative (e.g., ester, acid halogenide, acid amide, lactam, or the like) with a hydroxylamine or its hydrochloride which have a desirable R moiety under heating, if necessary, in the presence of a base (e.g., alkali alkoxide, alkali hydroxide, sodium hydrogencarbonate, or the like), (2) mild alkali hydrolysis of O,N-diacyl derivative, which is prepared by treatment of an acid anhydride with hydroxylamine, (3) addition of a hydroxylamine with a ketene (4) reaction of a nitro compound in the presence of sulfuric acid under mild condition, or (5) oxidation of a nitrogen containing compound (e.g., oxime, amine, imine, or the like) with a peroxide (e.g., peroxodisulfuric acid, hydrogen peroxide, or the like).

For example, the compound can be preferably prepared, as follows.

(A) When Y-R is -CO-N(OH)R.

Route 1



In the reaction scheme, X and R each have the same meaning as defined before and Z is a nucleophilic leaving group.

Step 1

In this step, a carboxylic acid derivative (II) is converted into the compound of this invention (IA).

In the reaction of the compound (II) wherein Z is hydroxy, with carboxylic acid activator, the activator such as thionyl chloride, phosphorus oxychloride, phosphorus pentachloride, chlorocarbonates (e.g., methyl chlorocarbonate, ethyl chlorocarbonate, isobutyl chlorocarbonate), oxalyl chloride, carbodiimides (e.g., N,N-dicyclohexylcarbodiimide (DCC)) or the like is used. Carbodiimides may be used together with p-nitrophenol or hydroxysuccinimide.

The reaction is carried out in a solvent such as a halogenated hydrocarbon (e.g., dichloromethane, chloroform), ether (e.g., diethyl ether, isopropyl ether, tetrahydrofuran, dioxane), N,N-dimethylformamide, or acetonitrile or mixtures thereof. The reaction temperature is usually -50°C to 50°C .

In this reaction when thionyl chloride, phosphorus oxychloride, oxalyl chloride, or phosphorus pentachloride is used as a carboxylic acid activator, an acid halide is prepared as a reactive derivative, when a chlorocarbonate is used, a mixed acid anhydride is prepared, and when carbodiimide is used, active ester is prepared


The reaction of the compound (II) with hydroxylamine is carried out as follows:

when the compound (II) is an acid halide, the reaction is carried out in a solvent such as dichloromethane, tetrahydrofuran, acetone, or the like in the presence of a base (e.g., pyridine, 4-dimethylaminopyridine, triethylamine, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, potassium hydrogencarbonate, sodium hydrogencarbonate, or the like) under dry or water containing conditions. The reaction temperature is about -30°C to about 50°C ; when the compound (II) is active ester or mixed acid anhydride, the reaction is carried out in the same solvent which is used in the reaction of the compound (II) wherein R is hydroxy, with a carboxylic acid activator. The reaction temperature is usually -20°C to 50°C and the reaction time is 1 to 5 hours.

The compound (II) wherein Z is hydroxy may be directly converted into hydroxamic acid in the presence of a condensing agent.

Route 2

30



45

In the reaction scheme, R_1 is hydroxy or halogen; Hal is halogen; X, Z, and R are each as defined before.

50

Step 1

In this step, a carboxylic acid derivative (IV) is converted into the hydroxamic acid (VA) having desirable "R" moiety through an acid halide.

The halogenation and the hydroxamic acid formation in this step can be carried out according to the same procedure as shown in Step 1 of Route 1. When R_1 is hydroxy, it is also halogenated at the same time in this step.

Step 2

In this step, the compound (VA) is allowed to react with 2,6-di-tert-butyl-4-mercaptophenol to give the compound (IA) of this invention.

5 The reaction is carried out in the presence of a base (e.g., sodium hydroxide, potassium hydroxide, calcium hydroxide, potassium carbonate, pyridine, 4-dimethylaminopyridine, triethylamine, or the like) in a solvent such as an alcohol (e.g., methanol, ethanol, propanol, tert-butanol, or the like), an ether (e.g., diethyl ether, tetrahydrofuran, or the like), N,N-dimethylacetamide, or acetonitrile under cooling, at room temperature, or under refluxing for 10 minutes to several tens of hours. When the reaction is carried out under
 10 conditions using an immiscible base with a solvent system, for example, using a base such as alkali hydroxide or alkali carbonate in a solvent such as an alcohol (e.g., methanol, ethanol, propanol, tert-butanol, or the like), halogenated hydrocarbon (e.g., dichloromethane, chloromethane, dichloroethane, or the like) or an aromatic hydrocarbon (e.g., benzene, toluene, or the like), the reaction may be carried out in the presence of a phase transfer catalyst such as tetra-n-butylammonium iodide in the single layer of the said
 15 solvent or two layers with water.

(B) When Y-R is -N(OH)CO-R.


20

Route 3

25

30

35



In the reaction scheme, X and R, each has the same meaning as defined before.

40

Step 1


In this step, an O,N-diacyl derivative (VI) is converted into the compound (IB) of the present invention.

45 This step is carried out by mild hydrolysis of the O,N-diacyl derivative (VI) with alkali hydroxide (e.g., lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide, or the like) by a usual manner.

The said O,N-diacyl derivative (VI) may be prepared as shown below.

50

55



Hal-X-N(OH)-CO-R

wherein Hal, X, and R, each have the same meaning as defined before.

The compounds (I) of this invention thus prepared can be isolated by conventional separation and purification methods (e.g. chromatography, crystallization, or the like).

5 The compounds (I) of this invention can strongly inhibit the incorporation of LDL into macrophages, the oxidation of lipid, the formation of ulcer, and/or action of lipoxygenase. Therefore, they are useful for the prevention and treatment of arteriosclerosis, gastric ulcer, allergic diseases, rheumatoid arthritis, myocardial ischemia, cataract, liver injury, cerebral cell disturbance, diabetes mellitus, thyroid function disorder, malignant tumor, inflammatory disease, or the like.

10 The compounds (I) of this invention can be administered orally or parenterally to patients. For the oral administration, they are normally formulated into conventional preparation form such as solid preparations (e.g., tablets, powders, capsules, granules) or liquid preparations (e.g., aqueous dispersion, oily suspension, syrups, elixirs). For the parenteral administration, they are usually applied injectionably, such as in aqueous solutions or oily dispersions. On the formulation of the above preparations, excipients, binding agent, 15 lubricants, solvents, solubilizers, emulsifiers, dispersants, and the like may be used. Other additives such as preservatives and stabilizing agents may be also used.

The dosage of the compounds (I) of this invention varies with the dosage form, age, bodyweight, symptom of the patient, or the like but usually ranges from about 5 to 1000 mg per day, preferably, 20 mg to 200 mg per day for oral administration and 1 mg to 500 mg per day, preferably, 5 mg to 50 mg per day 20 for parenteral administration. These may be administered in single or divided doses.


Practical and presently preferred embodiments for this invention are shown in the following Examples, but it should be understood that these examples are given only for illustrative purposes and do not limit the scope of the present invention thereto.

25

Example 1

30 N-Methyl-2-(3,5-di-tert-butyl-4-hydroxyphenyl)thioacetohydroxamic acid (I1)

30



To 20 ml of a solution of 1.48 g (5 mmol) of 2-(3,5-di-tert-butyl-4-hydroxyphenyl)thioacetic acid (II 1) in dichloromethane was added 555 mg (5.5 mmol) of triethylamine and 5 ml of a solution of 750 mg (5.5 mmol) of isobutyl chlorocarbonate in dichloromethane was added dropwise to the resulting mixture over about a 5 minute period under cooling at $-45^{\circ}\text{C} \pm 5^{\circ}\text{C}$ and stirring. The mixture was stirred for 1 hour at the same temperature. To the reaction mixture was added 450 mg (5.5 mmol) of N-methyl hydroxylamine hydrochloride and then added dropwise 5 ml of a solution of 1.21 g (12 mmol) of triethylamine in dichloromethane. The mixture was stirred at the same temperature for 30 minutes and then for an additional 2 hours after removal of the cooling bath. The reaction mixture was poured into 50 ml of a cold 5 % aqueous solution of hydrochloric acid and extracted with 50 ml of dichloromethane. The extract was washed twice with 50 ml of water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was chromatographed on silica gel. The fractions eluted with a mixture of ethyl acetate - n-hexane (2:1) were collected. From the first fraction, 892 mg of isobutyl 2-(3, 5-di-tert-butyl-4-hydrox-

yphenyl)thioacetate was obtained as a colorless oil in 55 % yield and the aimed compound (I1) obtained from the second fraction was recrystallized from a mixture of ether -n-hexane (1:1) to give 350 mg of colorless prismatic crystals in 21.5 % yield. Mp. 84 -85 ° C.


Analysis Calcd. (%) for $C_{17}H_{27}NO_3S$: C, 62.74; H, 8.36; N, 4.30; S, 9.85; Found: C, 62.67; H, 8.31; N, 4.39; S, 9.82.

IR ν max(Nujol) cm^{-1} : 3580, 3180(OH), 1625 (CO).

200MHz NMR($CDCl_3$) δ : 1.43(18H, s, $2 \times C(CH_3)_3$), 3.06(3H, s, NCH_3), 3.55(2H, broad, $-SCH_2-$), 5.34(1H, broad, $-OH$), 7.33(2H, s, $2 \times$ aromatic H).

Example 2


N-Methyl-3-(3,5-di-tert-butyl-4-hydroxyphenyl)thiopropohydroxamic acid (I2)



1) $ClCO_2Et/Et_3N$

2) $CH_3NHOH \cdot HCl$

Et_3N



To 30 ml of a solution of 2.17 g (7 mmol) of 3-(3,5-di-tert-butyl-4-hydroxyphenyl)thiopropionic acid (II 2) in dichloromethane was added 717 mg (7.1 mmol) of triethylamine and to the mixture was added 870 mg (8 mmol) of ethyl chlorocarbonate under stirring and ice-cooling. The resulting mixture was stirred for 30 minutes under ice-cooling, then 1.25 g (15 mmol) of methylhydroxylamine hydrochloride and 3.03 g (30 mmol) of triethylamine were added thereto, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into 50 ml of a 5 % aqueous solution of hydrochloric acid and extracted with 50 ml of dichloromethane. The extract was washed with 50 ml of water twice, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was chromatographed on silica gel and fractions eluted with a mixture of ethyl acetate -ether (3:1) were collected to give a crystalline residue which was recrystallized from a mixture of ether - n-hexane (1:1) to give 1.166 g of the aimed compound as colorless prismatic crystals in 49.1 % yield. Mp. 103 - 105 ° C.

Anal. Calcd. (%) for $C_{18}H_{29}NO_3S$: C, 63.68; H, 8.61; N, 4.13; S, 9.44; Found: C, 63.32; H, 8.59; N, 4.08; S, 9.24.

IR ν max(Nujol) cm^{-1} : 3605, 3590, 3180(OH), 1616(CO).

200MHz NMR($CDCl_3$) δ : 1.37(18H, s, $2 \times C(CH_3)_3$), 2.54(2H, broad, $-CH_2CO-$), 3.07(2H, t, $J = 7.5Hz$, $-SCH_2-$), 3.22(3H, s, NCH_3), 5.21(1H, broad, OH), 7.21(2H, s, $2 \times$ aromatic H).

Examples 3 to 7

According to the procedure shown in Example 2, the following compounds and the compounds shown

in Table 2 were prepared under the reaction conditions shown in Table 1.

Example 3

Preparation of N-methyl-4-(3,5-di-tert-butyl-4-hydroxyphenyl)thiobutyrohydroxamic acid (I3)

Example 4

6 Preparation of N-methyl-5-(3,5-di-tert-butyl-4-hydroxyphenyl)thiovalerohydroxamic acid (I4)

Example 5

Preparation of 5-(3,5-di-tert-butyl-4-hydroxyphenyl)thiovalerohydroxamic acid (I5)

Example 6

10 Preparation of N-methyl-6-(3,5-di-tert-butyl-4-hydroxy phenyl)thiocaprohydroxamic acid (I6)

Example 7

Preparation of N-methyl-4-(3,5-di-tert-butyl-4-hydroxyphenyl)thiomethylbenzohydroxamic acid (I7)

15

20

25

30

35

40

45

50

55





Table 1

Ex. No.	-X-	-R	Amount			ClO ₂ Et mg (mmol)	R-NHCl·HCl mg (mmol)	NEt, mg (mmol)	Purification	Yield mg (%)
			II mg (mmol)	NEt, mg (mmol)						
3	-(CH ₂) ₄ -	-CH ₃	1620 (5)	555 (5.5)		650 (6)	540 (6.5)	1520 (15)	Recrystallization (ether)	965 (55.8)
4	-(CH ₂) ₄ -	-CH ₃	1690 (5)	555 (5.5)		650 (6)	540 (6.5)	1520 (15)	Recrystallization (ether-methanol)	1530 (83.3)
5	-(CH ₂) ₄ -	-H	340 (1)	121 (1.2)		120 (1.1)	105 (1.5)	303 (15)	1) Column chromatography on silica gel (ethyl acetate) 2) Recrystallization (ether - n-hexane (1:1))	210 (59.4)
6	-(CH ₂) ₄ -	-CH ₃	2390 (6.78)	707 (7)		760 (7)	835 (10)	2020 (20)	Recrystallization (ether-methanol)	2080 (80.4)
7		-CH ₃	2980 (8)	909 (9)		977 (9)	835 (10)	2020 (20)	1) Column chromatography on silica gel (ether - ethyl acetate (1:1)) 2) Recrystallization (ether - n-hexane (1:1))	1210 (37.7)

5

10

15

20

25

30

35

40

45

50

55






Table 2

Ex. No.	-X-	-R	Appearance	Mp. (°C)	IR ν_{\max} Nujol (cm ⁻¹)	200 MHz NMR δ ppm (CDCl ₃)	Analysis (Molecular Formula) Calcd. (%) Found (%)
3	-(Cl ₂) ₂ -	-Cl ₂	Colorless prismatic crystal	112~ 113	3500. 3580. 3185(OH). 1595(CO).	1.37(18H, s, 2xC(Cl ₂)), 1.92(2H, quint, -Cl ₂ CH ₂ Cl ₂ -), 2.46(2H, broad, -Cl ₂ CO-), 2.85(2H, t, J=7Hz, -SCH ₂ -), 5.22(1H, broad, OH), 7.18(2H, s, 2xaromatic H).	(C ₁₂ H ₁₀ NO ₅ S) C. 64.55: H. 8.84: N. 3.96: S. 9.07 C. 64.31: H. 8.83: N. 3.94: S. 8.99
4	-(CH ₂) ₂ -	-CH ₂	Colorless, needle-like crystal	121~ 122	3595. 3100(OH). 1615sh(CO).	1.43(18H, s, 2xC(Cl ₂)), 1.63-1.90(4H, m, -Cl ₂ CH ₂ -), 2.39(2H, broad, Cl ₂ CO-), 2.85(2H, t, J=7Hz, -SCH ₂ -), 3.33(3H, s, NCH ₃), 5.22(1H, broad, OH), 7.23(2H, s, 2x aromatic H).	(C ₁₂ H ₁₀ NO ₅ S) C. 65.36: H. 9.05: N. 3.81: S. 8.72 C. 64.98: H. 9.04: N. 3.76: S. 8.64
5	-(CH ₂) ₂ -	-H	Colorless needle-like crystal	121~ 123	3600. 3280sh. 3200(OH). 1638(CO).	1.43(18H, s, 2xC(Cl ₂)), 1.61-1.88(4H, m, -Cl ₂ CH ₂ -), 2.19(2H, t, J=7.5Hz, -Cl ₂ CO-), 2.83(2H, t, J=7Hz, -SCH ₂ -), 5.22(2H, broad, OH), 7.22(2H, s, 2xaromatic H).	(C ₁₂ H ₁₀ NO ₅ S) C. 64.55: H. 8.84: N. 3.96: S. 9.07 C. 64.27: H. 8.83: N. 4.29: S. 9.36
6	-(CH ₂) ₂ -	-CH ₂	Colorless needle-like crystal	109~ 111	3600. 3120. 3040sh(OH). 1586(CO).	1.43(18H, s, 2xC(Cl ₂)), 1.44-1.78(6H, m, 3xCH ₂), 2.35 (2H, broad, -Cl ₂ CO-), 2.83(2H, t, J=7Hz, -SCH ₂ -), 3.33 (3H, s, NCH ₃), 5.20(1H, broad, OH), 7.22(2H, s, 2xaromat ic H).	(C ₁₂ H ₁₀ NO ₅ S) C. 66.10: H. 9.25: N. 3.67: S. 8.40 C. 65.85: H. 9.18: N. 3.62: S. 8.30
7	-Cl ₂ - 	-CH ₂	Colorless prismatic crystal	119~ 120	3600. 3220(OH). 1637(CO).	1.37(18H, s, 2xC(Cl ₂)), 3.41(3H, s, NCH ₃), 3.98(2H, s, -SCH ₂ -), 5.28(1H, broad, OH), 7.10(2H, s, 2xaromatic H), 7.25, 7.45(ench 2H, AR, J _{ax} =7.5Hz, 4xaromatic H).	(C ₁₂ H ₁₀ NO ₅ S) C. 68.79: H. 7.78: N. 3.49: S. 7.98 C. 68.74: H. 7.71: N. 3.35: S. 7.88

Example 8

N-n-Heptyl-5-(3,5-di-tert-butyl-4-hydroxyphenyl)thiovalerohydroxamic acid (I8)



A mixture of 1.5 g (8.3 mmol) of 5-bromovaleric acid and 1 ml of thionyl chloride was heated for 1 hour at 50 °C and the remaining thionyl chloride was evaporated under reduced pressure to give the crude 5-bromovaleryl chloride (IV1'). To a mixture of 50 ml of a solution of 1.31 g (10 mmol) of n-heptylhydroxylamine in dichloromethane and 20 ml of an aqueous solution of 1.38 g (10 mmol) of potassium carbonate was added dropwise 50 ml of a solution of the compound (IV1') in dichloromethane under stirring and ice-cooling. After addition, the mixture was stirred for 2 hours at room temperature. Into the reaction mixture was poured 50 ml of a 5% aqueous solution of hydrochloric acid. The separated dichloromethane layer was washed with 50 ml of water twice, dried over anhydrous sodium sulfate, concentrated under reduced pressure to give the crude product (V1) as a pale yellow oil. The oil was chromatographed on silica gel and from the fractions eluted with a mixture of ether -n-hexane (1:1), 1.66 g of the pure product (V1) was prepared in 68 % yield as colorless oil. To 5 ml of a solution of 560 mg (1.9 mmol) of the compound (V1) in ethanol are added 477 mg (2 mmol) of 2,6-di-tert-butyl-4-mercaptophenol and 1 ml of an aqueous solution of 200 mg of sodium hydroxide and the mixture was stirred for four hours at room temperature. To the reaction mixture which was cooled in an ice bath was added 20 ml of a 5 % aqueous solution of hydrochloric acid and the resulting mixture was extracted with 50 ml of ether. The ether layer was washed with 50 ml of water twice, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The oily residue was chromatographed on silica gel and 370 mg of the aimed compound (I8) was obtained in 43 % yield as a pale yellow oil from the fraction eluted with ether.


Anal. Calcd. (%) for C₂₆H₄₅NO₃S: C, 69.13; H, 10.04; N, 3.10; S, 7.10; Found (%): C, 68.84; H, 9.93; N, 3.11; S, 6.97.

IR_{max}(film)cm⁻¹: 3640, 3180(OH), 1615(CO).

200 MHz NMR δ ppm(CDCl₃): 0.83(3H, t, J=7Hz, -CH₂CH₃), 1.24 (10H, s, 5xCH₂), 1.38(18H, s, 2xC-(CH₃)₂), 1.57-1.82(4H, m, 2xCH₂), 2.28 (2H, broad, -CH₂CO-), 2.80(2H, t, J=7Hz, -SCH₂-), 3.55(2H, t, J=7Hz, -NCH₂-), 5.20(1H, broad, OH), 7.17(2H, s, 2xaromatic H).

Example 9


N-Cyclohexyl-5-(3,5-di-tert-butyl-4-hydroxyphenyl)thiovalerohydroxamic acid (I9)



The compound (IV1') which was prepared from 1.81 g (10 mmol) of 5-bromovaleric acid (IV1) and 1 ml of thionyl chloride according to the procedure shown in Example 8 was allowed to react with 1.75 g (11.5 mmol) of N-cyclohexylhydroxylamine hydrochloride to give the crude N-cyclohexyl-5-bromovalerohydroxamic acid (V2) as a pale yellow oil. Without further purification the oil was added to 20 ml of a solution of 2.83 g (10 mmol) of 2,6-di-tert-butyl-4-mercaptophenol in ethanol and then 10 ml of an aqueous solution of 1 g (25 mmol) of sodium hydroxide was added thereto and the mixture was stirred for 4 hours at room temperature. To the reaction mixture was added 50 ml of a 5% aqueous solution of hydrochloric acid under ice-cooling and the mixture was extracted with 100 ml of dichloromethane. The organic layer was washed with 100 ml of water twice, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crystalline residue, which was recrystallized from ether containing small amount of methanol to give 1.82 g of the aimed compound (I9) as colorless prismatic crystals in 49.6 %. The physical data are shown in Table 3.

Example 10

N-Methyl-7-(3,5-di-tert-butyl-4-hydroxyphenyl)thioheptanohydroxamic acid (I10)




A mixture of 1.64 g (10 mmol) of 7-chloroheptanoic acid and 1 ml of thionyl chloride was heated for 2 hour at 40 °C to 50 °C and the remaining thionyl chloride was evaporated under reduced pressure. A solution of the residue in 10 ml of dichloromethane was added dropwise to 10 ml of an aqueous solution of 1.66 g (12 mmol) of potassium carbonate containing 835 mg (10 mmol) of N-methyl hydroxylamine under stirring and ice-cooling. After addition, the mixture was stirred for 2 hours at room temperature. The reaction

mixture was cooled under ice-cooling and 20 ml of a 5% aqueous solution of hydrochloric acid was poured thereto. The mixture was extracted with 50 ml of dichloromethane and the dichloromethane layer was washed with 50 ml of water twice, dried over anhydrous sodium sulfate, concentrated under reduced pressure to give the crude N-methyl-7-chloroheptanohydroxamic acid (V3) as a pale yellow oil. The oil was subjected to the following reaction without further reaction. To a solution of 1.94 g (10 mmol) of compound (V3) and 2.83 g (10 mmol) of 2,6-di-tert-butyl-4-mercaptophenol in 50 ml of ethanol were added 1.52 g (11 mmol) of potassium carbonate and 50 mg of N-tetra-n-butylammonium iodide. The mixture was refluxed for 4 hours under heating and ethanol was evaporated. To the resulting residue was added 50 ml of a 5% aqueous solution of hydrochloric acid and the mixture was extracted with 50 ml of dichloromethane. The dichloromethane layer was washed with 50 ml of water twice, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give an oily residue. The oil was chromatographed on silica gel to give 2.89 g of the aimed compound (II0) in 73 % yield as a colorless to pale yellow oil from the fraction eluted with ether.

15

Example 11

N-Methyl-8-(3,5-di-tert-butyl-4-hydroxyphenyl)thiooctanohydroxamic acid (I11)



A mixture of 2.23 g (10 mmol) of 8-bromooctanoic acid (IV3) and 1 ml of thionyl chloride was heated for 1 hour at 50 °C and the remaining thionyl chloride was evaporated under reduced pressure. The resulting product was treated with 835 mg (10 mmol) of N-methyl hydroxylamine hydrochloride and 1.66 g (12 mmol) of potassium carbonate according to the procedure shown in Example 10 to give methyl-8-bromooc-tanohydroxamic acid (V4), which was recrystallized from a mixture of ether - n-hexane (1:1) to give 2.12 g of the compound (V4) as colorless prismatic crystals mp. 39 °C to 40 °C. To a solution of 2.12 g (8.4 mmol) of the compound (V4) and 2.15 g (9 mmol) of 2,6-di-tert-butyl-4-mercaptophenol in ethanol was added of 1.05 g (26.3 mmol) of sodium hydroxide and the resulting mixture was stirred for 4 hours at room temperature. The reaction mixture was poured into 50 ml of a 5% aqueous solution of hydrochloric acid and the mixture was extracted with 100 ml of ether. The ether layer was washed with 100 ml of water twice, dried over anhydrous sodium sulphate, and concentrated under reduced pressure to give an oily residue which was chromatographed on silica gel. The aimed compound (II1) which was obtained from the fraction eluted with a mixture of ether - ethyl acetate (2:1) was recrystallized from n-hexane containing a small amount of ether to give 2.99 g of colorless needle-like crystals in 87 % yield.

The physical data are shown in Table 3.

55

Example 12

N-Methyl-9-(3,5-di-tert-butyl-4-hydroxyphenyl)thiononano hydroxamic acid (I12)



25

30

Example 13

35




65

2.46 g of the compound (V6) as colorless prismatic crystals in 83.6 % yield. mp 49 °C to 51 °C. To a solution of 2.11 g (7.2 mmol) of the compound (V6) was allowed to react with 1.71 g (7.2 mmol) of 3,5-di-tert-butyl-4-hydroxythiophenol under the condition shown in Example 11. The prepared product was chromatographed and eluted with a mixture of ether - ethyl acetate (2:1) to give 3.12 g of the aimed compound (I13) as a pale yellow in 96.3 % yield.

The physical data are shown in Table 3

Example 14

N-Methyl-12-(3,5-di-tert-butyl-4-hydroxyphenyl)thiododecahydroxamic acid (I14)



According to the procedure shown in Example 11, 1.4 g (5 mmol) of 12-bromododecanoic acid (IV6) was treated with 1 ml of thionyl chloride and the resulting product was treated with 500 mg (6 mmol) of methylhydroxylamine hydrochloride and 900 mg (6.5 mmol) of potassium carbonate to give N-methyl-12-bromododecahydroxamic acid (V7), which was recrystallized from a mixture of ether - n-hexane (1:1) to give 1.16 g of the compound (V7) as colorless leaflet-like crystals in 75.3 % yield. mp. 53 °C to 55 °C. To a solution of 1.16 g (3.76 mmol) of the compound (V7) and 900 mg (3.76 mmol) of 2,6-di-tert-butyl-4-mercaptophenol were treated with a mixture of 10 ml of an aqueous solution of 420 mg (10.5 mmol) of sodium hydroxide and 20 ml of ethanol according to the Example 11. The prepared product was chromatographed and the product obtained from the fraction eluted with a mixture of ether - ethyl acetate (2:1) was recrystallized from n-hexane containing a small amount of ether to give 1.124 g of the aimed compound (I14) as colorless needle-like crystals in 64.2 % yield

The physical data are shown in Table 3.




Table 3 (No. 1)


Ex. No.	X	R	Mp. (°C)	IR ν_{\max} (cm ⁻¹)	200 MHz NMR δ ppm (CDCl ₃)	Analysis (Molecular Formula) Calcd. (%): Found (%):
9	(CH ₃) ₄	Cyclohexyl	146-148	Nujol 3580. 3140(OH). 1604. 1585. 1570(CO).	1.43(18H, s, 2×C(CH ₃) ₂), 1.60-1.89(14H, m, 7×CH ₂), 2.32-2.42(2H, broad, -CH ₂ CO-), 2.86(2H, t, J=7Hz, -SCH ₂ -), 3.60-3.80(1H, broad, N-CH), 5.19(1H, broad, OH), 7.22(2H, s, 2×aromatic H).	(C ₂₁ H ₂₈ NO ₂ S) C. 68.92: H. 9.49: N. 3.22: S. 7.36 C. 68.81: H. 9.60: N. 3.11: S. 7.20
10	(CH ₃) ₄	CH ₃		film 3615. 3150(OH). 1600(CO).	1.34-1.74(8H, m, 4×CH ₂), 1.44(18H, m, 2×C(CH ₃) ₂), 2.31-2.33(2H, broad, -COCH ₂ -), 2.83(2H, t, J=7Hz, -SCH ₂ -), 3.33(3H, s, NCH ₃), 5.19(1H, broad, OH), 7.22(2H, s, 2×aromatic H).	(C ₂₁ H ₂₈ NO ₂ S) C. 66.78: H. 9.43: N. 3.54: S. 8.10 C. 66.53: H. 9.32: N. 3.46: S. 7.92
11	(CH ₃) ₇	CH ₃	72-73	Nujol 3635. 3145. 3060(OH). 1627sh. 1605(CO).	1.29-1.40(6H, m, 3×CH ₂), 1.43(18H, s, 2×C(CH ₃) ₂), 1.56-1.75(4H, m, 2×CH ₂), 2.27-2.43(2H, broad, -CH ₂ CO-), 2.82(2H, t, J=7Hz, -SCH ₂ -), 3.35(3H, s, NCH ₃), 5.19(1H, broad, OH), 7.23(2H, s, 2×aromatic H).	(C ₂₁ H ₂₈ NO ₂ S) C. 67.44: H. 9.60: N. 3.42: S. 7.83 C. 67.58: H. 9.58: N. 3.52: S. 7.93

Table 3 (NO. 2)

Ex. No.	n	R	Mp. (°C)	IR ν_{\max} (cm ⁻¹)	200 MHz NMR δ ppm (CDCl ₃)	Analysis (Molecular Formula) Calcd. (X): Found (X):
12	(CH ₂) ₈	Cl ₂		film 3640. 3180(OH). 1615(CO).	1.28-1.40(8H, m, 4xCl ₂), 1.42(18H, s, 2x(CCl ₂)), 1.55-1.80(4H, m, 2xCl ₂), 2.27-2.40(2H, broad, -CH ₂ CO-), 2.82(2H, t, J=7Hz, -SCl ₂), 3.35(3H, s, NCH ₃), 5.20(1H, broad, OH), 7.22(2H, s, 2xaromatic H).	(C ₂₁ H ₁₁ NO ₅ S) C. 68.04: H. 9.76: N. 3.31: S. 7.57 C. 67.89: H. 9.68: N. 3.23: S. 7.48
13	(CH ₂) ₁₀	Cl ₂		film 3640. 3185(OH). 1615(CO).	1.22(12H, s, 6xCl ₂), 1.37(18H, s, 2x(CCl ₂)), 1.53-1.72(4H, m, 2xCl ₂), 2.28(2H, broad, -CH ₂ CO-), 2.77(2H, t, J=7Hz, -SCl ₂), 3.29(3H, s, NCH ₃), 5.20(1H, broad, OH), 7.17(2H, s, 2xaromatic H).	(C ₂₃ H ₁₃ NO ₅ S) C. 69.13: H. 10.04: N. 3.10: S. 7.10 C. 68.83: H. 9.92: N. 3.04: S. 6.82
14	(CH ₂) ₁₁	Cl ₂	76-77	Nujol 3640. 3160. 3060(OH). 1630. 1605(CO).	1.25(14H, s, 7xCl ₂), 1.43(18H, s, 2x(CCl ₂)), 1.53-1.75(4H, m, 2xCl ₂), 2.34(2H, broad, -CH ₂ CO-), 2.82(2H, t, J=7Hz, -SCl ₂), 3.35(3H, s, NCH ₃), 5.18(1H, broad, OH), 7.23(2H, s, 2xaromatic H).	(C ₂₄ H ₁₅ NO ₅ S) C. 69.36: H. 10.17: N. 3.01: S. 6.88 C. 69.50: H. 10.19: N. 3.04: S. 7.09

Example 15

N-5-(3,5-Di-tert-butyl-4-hydroxyphenylthio)pentyl-acetohydroxamic acid (I15)



A mixture of 990 mg (3.07 mmol) of 5-(3,5-di-tert-butyl-4-hydroxyphenylthio)valeroaldehyde (VII), 1.0 g (14.4 mmol) of hydroxylamine hydrochloride, and 10 ml of pyridine in 20 ml of ethanol was refluxed for 6 hours under beating and the reaction mixture was concentrated under reduced pressure. To the residue was added 20 ml of a 5% aqueous solution of hydrochloric acid and the mixture was extracted with 50 ml of dichloromethane. The organic layer was washed with 50 ml of water twice, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 1.01 g of an oily residue. To a solution of the residue in 30 ml of dry tetrahydrofuran was added dropwise 7.3 ml (7.3 mmol) of 1M solution of borane in tetrahydrofuran under ice-cooling and stirring, the mixture was stirred for 4 hours at the same temperature and then 5 ml of a 10 % aqueous solution of sodium hydroxide was added dropwise thereto. After addition, the resulting mixture was stirred for 30 minutes at room temperature and the reaction mixture was extracted with 100 ml of dichloromethane. The dichloromethane layer was washed with 100 ml of water twice, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a residue as yellow oil. To a solution of the residue in 20 ml of acetic anhydride was added 10 ml of pyridine and the mixture was allowed to stand for 20 hours at room temperature. The reaction mixture was concentrated under reduced pressure and the residue was chromatographed on silica gel to give 710 mg of aceto N-5-(3,5-di-tert-butyl-4-hydroxyphenylthio)pentyl-acetohydroxamate (VI) as a pale yellow oil in 62 % yield from the fraction eluted with ether.

To a solution of 710 mg (1.67 mmol) of the compound (VI) in 20 ml of methanol was added 280 mg (6.67 mmol) of lithium hydroxide and the mixture was stirred for 1 hour at room temperature. The reaction mixture was concentrated under reduced pressure and 20 ml of a 10 % aqueous solution of hydrochloric acid was added to the residue under ice-cooling. The mixture was extracted with 50 ml of ether and the ether layer was washed with 50 ml of water twice, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was chromatographed on silica gel to give the aimed compound (I15) from the fraction eluted with a mixture of ether - ethyl acetate (3:1) and the product was recrystallized from ether - n-hexane (1:1) to give 530 mg of the the compound (I15) as colorless needle-like crystals in 83 % yield.

mp. 103 °C to 105 °C.

Anal. Calcd. (%) for $C_{21}H_{35}NO_3S$: C, 66.10; H, 9.25; N, 3.67; S, 8.40; Found (%): C, 65.90; H, 9.16; N, 3.65; S, 8.37.

IR_{max}(Nujol)cm⁻¹: 3600, 3105, 2630(OH), 1575, 1520(CO).

200MHz NMR(CDCl₃) δ : 1.38-1.53(2H, m, CH₂), 1.43(18H, s, 2×C(CH₃)₃) 1.60-1.80(4H, m, 2×CH₂), 2.09-(3H, s, COCH₃), 2.84(2H, t, J=7Hz, -SCH₂-), 3.61(2H, t, J=7Hz, -NCH₂-), 5.21(1H, s, -OH), 7.23(2H, s, 2×aromatic H).

Example 16

N-5-[(3,5-di-tert-butyl-4-hydroxyphenylthio)pentyl]isobutyrohydroxamic acid (I16)


15

20

25

30

35



According to the procedure shown in Example 15, 990 mg (3.07 mmol) of 5-(3,5-di-tert-butyl-4-hydroxyphenylthio)valeraldehyde (VII) was allowed to react with 1.0 g (14.4 mmol) of hydroxylamine hydrochloride in 20 ml of ethanol in the presence of 10 ml of pyridine to give an oxime intermediate of which solution in 30 ml of dry tetrahydrofuran was reduced by 7.3 ml (7.3 mmol) of 1M solution of boran in tetrahydrofuran to give the crude 5-(3,5-di-tert-butyl-4-hydroxyphenylthio)pentylhydroxylamine as a pale yellow oil. To a solution of the oil in 20 ml of dichloromethane was added 10 ml of aqueous solution of 690 mg (5 mmol) of potassium carbonate and to the resulting mixture was added dropwise a solution of 640 mg (6 mmol) of isobutyryl chloride under ice-cooling and vigorous stirring. After addition, the mixture was stirred for 30 minutes at the same temperature, the dichloromethane layer was separated, washed with 50 ml of water twice, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was chromatographed to give 417 mg of isobutyl N-5-(3,5-di-tert-butyl-4-hydroxyphenylthio)pentylisobutyrylhydroxamic acid (VI2) as a pale yellow oil in 28.3 % yield.

To a solution of 417 mg of the compound (VI2) in 15 ml of methanol was added 250 mg (6 mmol) of lithium hydroxide and the mixture was stirred for 1 hour at room temperature. The reaction mixture was concentrated under reduced pressure. The product which was prepared by treating the residue according to the procedure shown in Example 15 was chromatographed to give the aimed compound (I16) from the fraction eluted with a mixture of ether - n-hexane (1:1). The aimed compound (I16) was recrystallized from n-pentane to give 295 mg of prismatic crystals in 82.8 % yield.

mp. 109 °C to 111 °C.

Anal. Calcd. (%) for $C_{23}H_{39}NO_3S$: C, 67.44; H, 9.60; N, 3.42; S, 7.83; Found (%): C, 67.18; H, 9.62; N, 3.36; S, 7.78.


IR_{max}(Nujol)cm⁻¹: 3590, 3120(OH), 1622, 1605(CO).

200MHz NMR(CDCl₃)δ : 1.11(6H,d,J=7Hz,2xCH₃), 1.37(18H, s, 2xC(CH₃)₃), 1.40-1.47(2H, m, CH₂), 1.53-1.72(4H, m, 2xCH₂), 2.72(1H, broad, CH), 2.78(2H, t, J=7Hz, -SCH₂-), 3.58(2H, t, J=7Hz, -NCH₂-), 5.26(1H, broad, -OH), 7.17(2H, s, 2xaromatic H).

5

Example 17

10 N-5-[(3,5-di-tert-butyl-4-hydroxyphenylthio)pentyl]benzohydroxamic acid (I17)



According to the procedure shown in Example 15, a mixture of 968 mg (3.0 mmol) of the compound (VII), 1.0 g (14.4 mmol) of hydroxylamine hydrochloride, and 10 ml of pyridine in 20 ml of ethanol was refluxed under heating to give the oxime which was treated with 7 ml (7 mmol) of an 1M solution of boran in tetrahydrofuran to give the crude N-5-(3,5-di-tert-butyl-4-hydroxyphenylthio)pentylhydroxylamine. To a solution of the crude compound in 20 ml of dichloromethane was added 10 ml of an aqueous solution of 690 mg (5 mmol) of potassium carbonate and the mixture was stirred vigorously. The product was chromatographed on silica gel to give 411 mg of benzoyl N-5-[3,5-di-tert-butyl-4-hydroxyphenylthio)pentyl]-benzoylhydroxamate (VI3) as a colorless oil in 25 % yield from the fraction eluted with a mixture of ether -n-hexane (1:1). According to the procedure shown in Example 15, 411 mg (0.75 mmol) of the compound (VI3) was treated with 250 mg (6 mmol) of lithium hydroxide in 15 ml of methanol and the resulting product was chromatographed on silica gel to give the aimed compound (I17) from the fraction eluted with a mixture ether - n-hexane (1:1). The compound (I17) was recrystallized from n-pentane containing small amount of ether to give 205 mg of the compound as colorless needle-like crystals.

mp. 67 °C to 69 °C.

Anal. Calcd. (%) for $\text{C}_{26}\text{H}_{37}\text{NO}_3\text{S}$: C, 70.39; H, 8.41; N, 3.16; S, 7.23; Found (%) : C, 70.26; H, 8.40; N, 3.34; S, 7.05.


IR_{max}(Nujol)cm⁻¹: 3640, 3120sh(OH), 1610, 1600(CO).

200MHz NMR(CDCl₃)δ : 1.30-1.47(2H, m, CH₂), 1.42(18H, s, 2xC(CH₃)₃), 1.50-1.82(4H, m, 2xCH₂), 2.79(2H, t, J=7Hz, -SCH₂-), 3.64(2H, t, J=7Hz, -NCH₂-), 5.20(1H, broad, -OH), 7.21(2H, s, 2xaromatic H), 7.40-7.55-(5H, m, 5xaromatic H).

55

Example 18

N-Benzyl-5-(3,5-di-tert-butyl-4-hydroxyphenylthio)valerohydroxamic acid (I18)




20 According to the procedure shown in Example 8, 724 mg (4 mmol) of 5-bromovaleric acid (IV1) was treated with about 1 ml of thionyl chloride to give the compound (IV1') which was allowed to react with 493 mg (4 mmol) of N-benzylhydroxylamine in the presence of 560 mg (4 mmol) of potassium carbonate to give crude N-benzyl 5-bromovalerohydroxamic acid (V8) as a pale yellow oil. Without further purification, the crude product was added to 10 ml of a solution of 960 mg (4 mmol) of 3,5-di-tert-butyl-4-hydroxythiophenol in ethanol and then 5 ml of an aqueous solution of 320 mg (8 mmol) of sodium hydroxide was added thereto. The mixture was stirred for 5 hours at room temperature. To the reaction mixture was added 20 ml of a 5 % aqueous solution of hydrochloric acid under ice-cooling and the mixture was extracted with 50 ml of dichloromethane. The organic layer was washed with 50 ml of water twice, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crystalline residue which was recrystallized from a mixture of ether- methanol (10:1) to give 1.31 g of the aimed compound (I18) as colorless laminar crystals in 73.8 % yield.

The physical data are shown in Table 4.

35 Example 19

N-2-(Phenyl)ethyl 5-(3,5-di-tert-butyl-4-hydroxyphenyl)thiovalerohydroxamic acid (I19)




The aimed compound (I19) was prepared according to the procedure shown in Example 18 except that N-2-(phenyl)ethyl hydroxylamine was used instead of N-benzylhydroxylamine. The compound was recrystallized from a mixture ether-n-hexane (1:1) to give colorless prismatic crystals in 70.5 % yield.

The physical data are shown in Table 4.

55 Example 20


N-Benzyl 6-(3,5-di-tert-butyl-4-hydroxyphenyl)thiocaprohydroxamic acid (I20)



The aimed compound (120) was prepared in 76.5 % yield as colorless prismatic crystals according to the procedure shown in Example 8 except that 6-bromocaproic acid was used instead of 5-bromovaleric acid. The physical data are shown in Table 4.

Example 21

N-2-(Phenyl)ethyl 6-(3,5-di-tert-butyl-4-hydroxyphenylthio)caprohydroxamic acid (121)



The aimed compound (121) was prepared according to the procedure shown in Example 8 except that 6-bromocaproic acid was used instead of 5-bromovaleric acid and that N-2-(phenyl)ethylhydroxylamine was used instead of N-benzyl hydroxylamine. The product was recrystallized from a mixture of ether - n-hexane to give colorless needle like crystals in 78.4 % yield.

The physical data are shown in Table 4.

Table 4

Ex. No.	mp. [°C]	IR, max [cm ⁻¹] (Nujol)	NMR δ ppm(CDCl ₃)	Analysis (Molecular Formula) Calcd. (%): Found (%):
18	143-145	3580, 3210, 1615, 1600	1.42(18H, s, 2×C(CH ₃)), 1.60-1.90(4H, m, 2×CH ₂), 2.42(2H, broad, -CH ₂ CO-), 2.83(2H, t, J=7Hz, -SCH ₂ -), 4.82(2H, s, -CH ₂ -Ph), 5.20(1H, s, -OH), 7.22(2H, s, 2×aromatic H), 7.29-7.38(5H, m, 5×aromatic H).	(C ₂₁ H ₁₉ NO ₂ S) C, 70.39; H, 8.41; N, 3.16; S, 7.23; C, 70.17; H, 8.46; N, 3.12; S, 7.29.
19	75-76	3640, 3620, 3160, 1620, 1602	1.43(18H, s, 2×C(CH ₃)), 1.46(4H, broad, 2×CH ₂ -), 1.83(2H, broad, -CH ₂ Ph), 2.70(2H, broad, -CH ₂ CO-), 2.98(2H, t, J=7Hz, -SCH ₂ -), 3.84(2H, t, J=6Hz, N-CH ₂ -), 5.23(1H, broad, -OH), 7.14-7.31(5H, m, 5×aromatic H), 7.20(2H, s, 2×aromatic H).	(C ₂₁ H ₁₉ NO ₂ S) C, 70.86; H, 8.59; N, 3.06; S, 7.01; C, 70.86; H, 8.54; N, 3.30; S, 6.84.
20	107 - 109	3580, 3190, 1610(sh), 1595.	1.17-1.39(2H, m, -CH ₂ -), 1.43(18H, s, 2×C(CH ₃)), 1.59-1.80(4H, 2×CH ₂ -), 2.41(1H, broad, -CH ₂ CO), 2.81(2H, t, J=7Hz, -SCH ₂ -), 4.82(2H, s, -CH ₂ Ph), 5.22(1H, broad, -OH), 7.22(2H, s, 2×aromatic H), 7.29-7.37(5H, m, 5×aromatic H).	(C ₂₁ H ₁₉ NO ₂ S) C, 70.86; H, 8.59; N, 3.06; S, 7.01; C, 70.81; H, 8.63; N, 3.02; S, 6.90.
21	87 - 89	3600, 3160, 1627, 1600.	1.41(18H, s, 2×C(CH ₃)), 1.30-1.65(6H, m, 3×CH ₂ -), 2.41(2H, t, J=7Hz, CH ₂ CO), 2.76(2H, t, J=7Hz, CH ₂ -Ph), 2.89(2H, t, J=7Hz, -SCH ₂ -), 3.80(2H, t, J=7Hz, -NCH ₂ -), 7.20-7.35(7H, m, 7×aromatic H).	(C ₂₁ H ₁₉ NO ₂ S) C, 71.30; H, 8.76; N, 2.97; S, 6.80; C, 71.28; H, 8.80; N, 3.11; S, 6.83.

Test Example 1

5

Suppression on Production of Peroxidized Lipids in a Homogenate of Rat Brain:

SD strain rats (body weight, about 200 g) were sacrificed by cutting off their heads, and the brains were
10 taken out. The brains were homogenated with a 4-fold amount of 0.05 M phosphate-sodium chloride buffer
(pH 7.4) and centrifuged at 1,000 x g for 10 minutes. The supernatant was kept at -80 °C for storage.

The supernatant was diluted with a 2-fold amount of the same phosphate - sodium chloride buffer as
above, and 0.45 ml of the dilution was combined with 30 µl of ethanol per se (vehicle) or ethanol solution
containing a test compound, followed by incubation at 37 °C for 30 minutes. The reaction was terminated
15 by addition of a solution of 0.1 % butylhydroxytoluene (BHT) (20 µl) in 25 % metaphosphoric acid (125 µl).
After deproteinization, the peroxidized lipids in the supernatant were measured by the thiobarbituric acid
(TBA) method according to the description by Ohkawa *et al.*; in Anal. Biochem., Vol. 95, page 351 (1979).
The amount of peroxidized lipids produced was compared with that in the vehicle applied group and
expressed in % control. The results are shown in Table 5.

20

25

30

35

40

45

50

55

Table 5 (No. 1)

Suppression on Production of Peroxidized Lipids in a
Homogenate of Rat Brain:

6

10

15

20

25

30

35

40

45

50

55

Test Compd. No.	Test Compd. Final Con- centration (mM)	Peroxidized Lipids Produced (% to Control)
<u>I 1</u>	0.001	71.9
	0.01	0
	0.1	0
<u>I 2</u>	0.001	42.0
	0.01	0
	0.1	0
<u>I 3</u>	0.001	44.2
	0.01	0
	0.1	0
<u>I 4</u>	0.001	28.6
	0.01	0
	0.1	0
<u>I 5</u>	0.0001	99.0
	0.001	37.4
	0.01	0
	0.1	0
<u>I 6</u>	0.001	37.2
	0.01	0
	0.1	0
<u>I 7</u>	0.0001	99.0
	0.001	63.6
	0.01	0
	0.1	0
<u>I 8</u>	0.0001	102.0
	0.001	1.5
	0.01	2.5
	0.1	0

Table 5 (No. 2)

Test Compd. No.	Test Compd. Final Con- centration (mM)	Peroxidized Lipids Produced (% to Control)
<u>I 9</u>	0.0001	97.0
	0.001	5.1
	0.01	0
	0.1	0
<u>I 1 0</u>	0.0001	94.2
	0.001	57.4
	0.01	1.6
	0.1	1.6
<u>I 1 1</u>	0.0001	97.4
	0.001	46.4
	0.01	0
	0.1	0
<u>I 1 2</u>	0.0001	94.5
	0.001	56.6
	0.01	0
	0.1	1.3
<u>I 1 3</u>	0.0001	93.3
	0.001	55.4
	0.01	0
	0.1	0
<u>I 1 4</u>	0.0001	95.3
	0.001	60.3
	0.01	0
	0.1	0
<u>I 1 5</u>	0.0001	97.3
	0.001	78.8
	0.01	1.6
	0.1	0

Table 5 (No. 3)

5

10

15

20

25

30

35

40

45

50

Test Compd. No.	Test Compd. Final Con- centration (mM)	Peroxidized Lipids Produced (% to Control)
<u>I 16</u>	0.001	89.5
	0.01	2.2
	0.1	0.3
<u>I 17</u>	0.001	77.6
	0.01	1.1
	0.1	0
<u>I 18</u>	0.001	84.9
	0.01	2.4
	0.1	1.1
<u>I 19</u>	0.001	81.6
	0.01	13.5
	0.1	0
<u>I 20</u>	0.001	81.9
	0.01	1.1
	0.1	0.3
<u>I 21</u>	0.001	86.8
	0.01	1.4
	0.1	0
Reference Compound	0.001	81.9
	0.001	102.4
	0.01	58.3
	0.1	27.8

Reference Compound: Probucol


It is understood from the above results that the compounds of this invention show an excellent anti-oxidation activity to lipids. And they thereby prevent the incorporation of LDL into macrophages by inhibiting the denaturation of LDL.

It can be expected that the compounds of this invention inhibit the formation of atheroma in the early stage of arteriosclerosis and that arrest the progression of arteriosclerosis.

Claims

1. A compound of the formula:

5



10

wherein X is straight or branched C_1 to C_{15} alkylene which may be attached to Y through phenylene, provided that X is not n-butylmethylene; Y is CO-N(OH) or N(OH)-CO; and R is hydrogen, straight or branched C_1 to C_9 alkyl, C_3 to C_9 cycloalkyl, aryl, or aralkyl, provided that R is not hydrogen when Y-R is N(OH)-CO-R; or a pharmaceutically or veterinarily acceptable salt thereof.


15

2. A compound as claimed in claim 1 wherein X is n-pentamethylene.

3. N-methyl-6-(3,5-di-tert-butyl-4-hydroxyphenylthio)caprohydroxamic acid.

4. A process for preparing a compound of the formula:

20




25

wherein X, Y, and R, are each as defined in claim 1 or a pharmaceutically or veterinarily acceptable salt thereof, which comprises either:

(1) reaction of a carboxylic acid derivative of the formula:

30



35

wherein X and Y, are each as defined in claim 1 and Z is a leaving group, with a hydroxylamine of the formula:

40

R-N(OH)H

wherein R is as defined in claim 1;

(2) reaction of 2,6-di-tert-butyl-4-mercaptophenol with a compound of the formula:


Hal-X-Y-R

wherein X, Y, and R are each as defined in claim 1 and Hal is halogen; or

45

(3) the hydrolysis of an O,N-diacyl derivative of the formula:


50



wherein X and R are each as defined in claim 1.

5. A pharmaceutical or veterinary formulation you use in the treatment or prophylaxis of atherosclerosis in mammals comprising a pharmacologically effective amount of at least one compound of the formula:

55



wherein X, Y and R are as defined in claim 1, or a pharmaceutically or veterinarily acceptable salt thereof, formulated for such use, and optionally in unit dosage form.

10 6. A pharmaceutically or veterinarily formulation as claimed in claim 5 which is formulated with one or more pharmaceutically or veterinarily acceptable diluent excipients, binding agents, lubricants, solvents, solubilizers, emulsifiers, dispersants, preservatives or stabilising agents.

7. A pharmaceutical or veterinary formulation as claimed in claim 5 or claim 6 which is formulated for oral or parenteral administration.


15 8. A pharmaceutical or veterinary formulation as claimed in any one of claims 5 to 7 which is formulated to provide a dose of from about 5 to 1000 mg per day provided as a single dose or as multiple doses.

9. A pharmaceutical or veterinarily formulation as claimed in any one of claims 5 to 8 wherein the at least one compound is N-methyl-6-(3,5-di-tert-butyl-4-hydroxy-phenylthio)caprohydroxamic acid.

20 10. The use of a compound as claimed in any one of claims 1 to 3 in the manufacture of a medicament for use in the treatment or prophylaxis of arteriosclerosis, gastric ulcers, allergic diseases, rheumatoid arthritis, myocardial ischemia, cataracts, liver injury, cerebral cell disturbance, diabetes mellitus, thyroid function disorder, malignant tumor, inflammatory diseases or the like.

Claims for the following Contracting States: ES and GR

25 1. A process for the production of a pharmaceutical or veterinary preparation for use in the treatment or prophylaxis of atherosclerosis in mammals, which process comprises admixing a pharmacologically effective amount of at least one compound of the formula:




wherein X is straight or branched C₁ to C₁₅ alkylene which may be attached to Y through phenylene, provided that X is not n-butylmethylene; Y is CO-N(OH) or N(OH)-CO; and R is hydrogen, straight or branched C₁ to C₉ alkyl, C₃ to C₉ cycloalkyl, aryl, or aralkyl, provided that R is not hydrogen when Y-R is N(OH)-CO-R; or a pharmaceutically or veterinarily acceptable salt thereof, with one or more pharmaceutically or veterinarily acceptable diluents excipients, binding agents, lubricants, solvents, solubilizers, emulsifiers, dispersants, preservatives or stabilising agents.

40 2. A process as claimed in claim 1 wherein the compound is N-methyl-6-(3,5-di-tert-butyl-4-hydroxyphenylthio)caprohydroxamic acid.

45 3. A process for making a compound as defined in the formula of claim 1 wherein said compound is produced by a process comprising either:

(1) reaction of a carboxylic acid derivative of the formula:



wherein X and Y, are each as defined in claim 1 and Z is a leaving group, with a hydroxylamine of the formula:

R-N(OH)H


wherein R is as defined in claim 1;

(2) reaction of 2,6-di-tert-butyl-4-mercaptophenol with a compound of the formula:

Hal-X-Y-R

wherein X, Y, and R are each as defined in claim 1 and Hal is halogen; or

5 (3) the hydrolysis of an O,N-diacyl derivative of the formula:



wherein X and R are each as defined in claim 1.

15 4. A process as claimed in claim 3 wherein the starting materials are chosen so that in the resulting compound X is n-pentamethylene.

5. A process as claimed in claim 3 wherein the starting materials are chosen so that the resulting compound is N-methyl-6-(3,5-di-tert-butyl-4-hydroxyphenylthio)caprohydroxamic acid.

20 6. A process as claimed in any one of claims 1 to 3 wherein the pharmaceutically or veterinarily acceptable preparation is formulated for oral or parenteral use.

7. A process as claimed in any one of claims 1 to 5 wherein the pharmaceutical or veterinarily acceptable preparation is formed into unit dosage form.

8. A process as claimed in claim 6 wherein the preparation is formulated to provide a dose of about 5 to 1000 mg per day, provided as a single dose or as multiple doses.

25

30

35

40

45

50

55